Charlotte Price

Company: Beacon Targeted Therapies

Job title: Manager, Small Molecules

Seminars:

Three Generations of DDR Therapeutics – Where Are We Now 8:10 am

• A landscape overview of the DDR Therapeutic landscape, focusing on the first generation of approved PARP inhibitors • A detailed look at the preclinical and clinical second generation DDR assets, including; specialized PARP-targeted assets, ATR, and WEE1 inhibitors • A review of a third generation of novel DDR targets, including POL-Theta, WRN, and PARGRead more

day: Day One